Turk Kardiyoloji Dernegi Arsivi, cilt.33, sa.8, ss.480-487, 2005 (Scopus, TRDizin)
Although aspirin is the most commonly used antithrombotic drug in the treatment of cardiovascular diseases, the appearance of vascular thromboembolic events in some patients receiving aspirin has brought into question its safety and development of aspirin resistance. This article reviews the most current information concerning the cause of aspirin resistance and clinical results and discusses therapeutic implications.